Baxter Appoints John Orloff, M.D., Vice President of BioScience R&D
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) today announced the appointment of John Orloff, M.D., as vice president and global head of research and development for Baxter BioScience, effective immediately. Dr. Orloff joins Baxter from Merck Serono Pharmaceuticals, where he served as global head of clinical development. Dr. Orloff will be responsible for advancing the late-stage BioScience pipeline, enhancing the current R&D operating model and pursuing additional innovative opportunities for the business.
''As we work toward becoming an independent global biopharmaceutical company, our priorities are to drive innovation by advancing our rich, late-stage development pipeline, expanding our expertise in immunology, hematology, and other core technologies and optimizing our R&D productivity,'' said Ludwig Hantson, Ph.D., president of Baxter BioScience. ''John brings significant scientific and leadership expertise, including preclinical research, clinical development, and medical and regulatory affairs. He will be a valuable member of our executive leadership team and a guiding force for effectively executing the development strategy for our organization.''
Prior to his tenure at Merck Serono, Dr. Orloff spent approximately 10 years at Novartis, where he served in roles of increasing responsibility including chief medical officer for global development. Earlier in his career, Dr. Orloff supported clinical development at Merck Research Labs and was previously a faculty member at the Yale University School of Medicine. Dr. Orloff’s expertise in bone biology contributed to marketing approvals for treatments for a range of bone disorders, and he has led programs across a diverse range of therapeutic areas, including immunology, neurology and oncology.
Dr. Orloff received an undergraduate degree in chemistry from Dartmouth College and earned his medical degree from the University of Vermont, College of Medicine and completed a fellowship in endocrinology and metabolism at Yale University School of Medicine.
About Baxter International Inc.
Baxter International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, cancer, infectious diseases, kidney disease, trauma and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.